ACOR - Acorda Therapeutics Inc.

ACOR Stock Chart

ACOR Profile

Acorda Therapeutics, Inc., a leading biopharmaceutical company headquartered in Ardsley, New York, focuses on pioneering therapies for neurological disorders across the United States and global markets. The company's flagship product, Ampyra (dalfampridine), is an oral medication approved to enhance walking ability in patients with multiple sclerosis (MS). Acorda also markets Inbrija, designed to alleviate OFF periods in individuals with Parkinson's disease, which is available in Europe, complementing its presence under the brand Fampyra across Europe, Asia, and the Americas.

In its commitment to innovation, Acorda Therapeutics continues to advance its pipeline with promising therapies. This includes ARCUS, a product in development for the acute treatment of migraines, and rHIgM22, which has successfully completed Phase I clinical trials for the treatment of MS. Additionally, the company is dedicated to addressing cardiovascular health with Cimaglermin alfa, an investigational therapy targeting heart failure patients.

Acorda Therapeutics operates through strategic collaborations, including a significant partnership with Biogen Inc. aimed at developing and commercializing Ampyra. Founded in 1995, the company remains at the forefront of neurology-focused research and development, driven by a mission to improve the lives of patients worldwide through innovative pharmaceutical solutions.

ACOR Revenue Chart

ACOR Earnings

Analyst Ratings